Pharmaceuticals
PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
Published in Medical Device Business Week, February 24th, 2010
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
"We are very pleased to move forward with this investigational treatment aimed at preventing bronchiolitis obliterans, which is an incurable small airway disease in lung transplant recipients. This study has been designed with advice from the European...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
More Articles from Medical Device Business Week
- Aloka COMPANY, LTD.
ALOKA's Diagnostic Ultrasound System ProSound Alpha 6 Presented 2010 iF Product Design Award - AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals Provides Feraheme(R) Safety Update - Amgen Inc.
Research from Amgen, Inc. broadens understanding of amgen inc. - Amphetamines
Studies from GlaxoSmithKline, Department of Biology provide new data on amphetamines - Angeion Corporation
Angeion to Announce 2010 First-Quarter Results on Wednesday, February 24 - Angiology
FlowCardia, Inc. Initiates CENTRAL Study Enrollment - More from this issue of Medical Device Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
